FD&C Act Section 501 - Adulteration

What it says

A drug is deemed adulterated if it consists of a filthy, putrid or decomposed substance, was prepared or held under insanitary conditions, or if the methods, facilities or controls used in its manufacture, processing, packing or holding do not conform to current good manufacturing practice, among other specified conditions.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This is the foundational legal provision that gives cGMP regulations their enforcement teeth - a cGMP violation is not simply a regulatory technicality, it is the specific legal basis under which a drug can be deemed adulterated under federal law.
• A product can be deemed adulterated under this section even without any evidence the specific batch is unsafe or ineffective - a manufacturing process that does not conform to cGMP is sufficient on its own, independent of finished product testing results.
• This provision underlies the legal authority behind FDA enforcement actions ranging from warning letters through seizure, injunction and criminal prosecution.

What FDA inspectors look for

• This is a statutory legal provision rather than a specific GMP practice inspectors check directly - it is the legal basis underlying essentially every cGMP-related enforcement action FDA takes based on findings during inspection.
• The practical connection for quality professionals is that any cGMP deficiency identified during inspection is potentially evidence supporting a Section 501 adulteration determination, which is why 483 observations are taken seriously regardless of whether a specific batch's quality is in question.

Related regulations